SeqWright's Partnership With Third Wave Contributes to FDA Success

HOUSTON, March 31 /PRNewswire/ -- SeqWright Inc. today congratulated Third
Wave Technologies Inc., Madison, Wis., on the successful FDA clearance of its
InPlex(TM) CF Molecular Test. CLIA-certified SeqWright is a leader in the
field of contract genomics and provided the FDA-level genotyping that
ultimately validated the InPlex(TM) CF test by demonstrating it had
99.96% overall agreement with DNA sequencing. The validation played a
critical role in the test gaining FDA clearance. SeqWright was responsible
for providing the sequence verification for 19 cystic fibrosis (CF) variants
from numerous patient samples.
The success of SeqWright's collaboration with Third Wave builds on a
relationship established in 2004, when the two companies began work on Third
Wave's UGT1A1 Molecular Assay. SeqWright provided FDA-level sequencing to
validate the UGT1A1 pharmacogenetic test, which is used to identify patients
susceptible to adverse reaction from a specific colorectal cancer treatment.
The assay gained FDA clearance in August 2005. SeqWright was selected for the
sequencing-based validation of Third Wave's InPlex(TM) CF test after the
exemplary work it performed with Third Wave's UGT1A1 Molecular Assay.
"We are grateful for the contributions SeqWright has made to Third Wave's
two successful FDA submissions," said Kevin T. Conroy, president and chief
executive of Third Wave.
SeqWright CEO, Fei Lu, M.D., said, "We are proud of the success of our
past and present collaborations with Third Wave Technologies and we are
excited to be involved in the validation of these important diagnostic tests."
About SeqWright:
SeqWright Incorporated is a world-class genomic services support
organization based in Houston, TX with more than a decade of experience
specializing in providing access to state of the art Molecular Biology and
Genomic services in a highly regulated GLP/CLIA environment. For additional
information about SeqWright and its services, please visit
http://www.seqwright.com.
About Third Wave Technologies:
Third Wave develops and markets molecular diagnostic reagents for a
variety of DNA and RNA analysis applications to meet the needs of our
customers. The company offers a number of products based on its Invader(R)
chemistry for clinical testing. Third Wave offers in vitro diagnostic kits,
and analyte specific, general purpose, and research use only reagents for
nucleic acid analysis. For more information about Third Wave and its
products, please visit the company's website at http://www.twt.com.
SOURCE SeqWright Inc.

Marc Dantone of SeqWright Inc., +1-713-528-4363, mdantone@seqwright.com